Literature DB >> 2333787

Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats.

D D Thompson1, J G Seedor, M Weinreb, S Rosini, G A Rodan.   

Abstract

The purpose of this study was to document the effects of aminobutane bisphosphonate (AHBuP) on bone remodeling during immobilization in rats. Male Sprague-Dawley rats underwent unilateral sciatic neurectomy after receiving two daily subcutaneous injections of 0, 0.01, 0.10, or 1.0 mg P per kg AHBuP. Rats were sacrificed at 24 h or 10 or 20 days postimmobilization. Femora were ashed and tibiae were prepared for histomorphometric analysis. AHBuP was effective in inhibiting bone loss due to immobilization in a dose-dependent manner. The percentage loss of femoral ash weight due to immobilization decreased in a dose-dependent manner. In vehicle-treated rats, there was a significant decrease in trabecular bone volume (TBV) in the immobilized tibiae compared to the normal tibiae; in AHBuP-treated rats there was a dose-dependent increase in TBV both in the immobilized and control tibiae. The osteoid surface extent was decreased in AHBuP-treated rats in a dose-dependent manner. The mineral apposition rate was altered only in the intact leg of rats treated with 0.1 and 1.0 mg P AHBuP per kg compared to vehicle treated. Osteoclast number per mm was reduced by AHBuP treatment. In conclusion, aminohydroxybutane bisphosphonate effectively prevented the bone loss due to immobilization in this system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2333787     DOI: 10.1002/jbmr.5650050312

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  13 in total

Review 1.  Modulation of bone calcium-binding sites regulates plasma calcium: an hypothesis.

Authors:  F Bronner; W D Stein
Journal:  Calcif Tissue Int       Date:  1992-06       Impact factor: 4.333

2.  Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.

Authors:  William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen
Journal:  J Bone Miner Metab       Date:  2014-08-27       Impact factor: 2.626

3.  The effect of bilateral oophorectomy on bone mineral density.

Authors:  Alper Hayirlioglu; Hüsnü Gökaslan; Nurten Andaç
Journal:  Rheumatol Int       Date:  2006-05-20       Impact factor: 2.631

4.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

5.  Alendronate does not prevent long bone fragility in an inactive rat model.

Authors:  K Naruse; K Uchida; M Suto; K Miyagawa; A Kawata; K Urabe; M Takaso; M Itoman; Y Mikuni-Takagaki
Journal:  J Bone Miner Metab       Date:  2015-10-16       Impact factor: 2.626

6.  Effects of risedronate on femoral bone mineral density and bone strength in sciatic neurectomized young rats.

Authors:  Jun Iwamoto; Azusa Seki; Tsuyoshi Takeda; Yoshihiro Sato; Harumoto Yamada
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

Review 7.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

8.  The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.

Authors:  M Yamamoto; A Markatos; J G Seedor; P Masarachia; M Gentile; G A Rodan; R Balena
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

9.  Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties.

Authors:  J A Guy; M Shea; C P Peter; R Morrissey; W C Hayes
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

10.  The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.

Authors:  R Balena; B C Toolan; M Shea; A Markatos; E R Myers; S C Lee; E E Opas; J G Seedor; H Klein; D Frankenfield
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.